30results about How to "Target-specific" patented technology

The invention relates to a sodium alginate micro ball vessel suppository which contains soluble medicine, and relative preparation and application, wherein said agent can be divided into two kinds as wet ball and dry ball made from degradable biological material; said carrier comprises sodium alginate, blood serum albumin, chitose, or transparent sodium solution, via the static to be solidified with calcium ion, to be made into the micro ball at 20 mum-1000 mum. The inventive material has high mechanical strength, biological compatibility, biological degradability and stability. The invention can be used to cure the vessel suppository of variable cancers.

The invention relates to a method for preparing an oxygen deficiency semiconductor nitrogen dioxide gas-sensitive coating.A single crystal silicon wafer Si is adopted as an insulating substrate.An interdigitated electrode and a terminal are prepared on the front side of the insulating substrate, inorganic salt powder is dissolved in deionized water or in an organic solvent and stirred to obtain an uniform solution serving as a precursor, the precursor is conveyed to flame flow through a non-atomizing nozzle, the flame flow is generated by a plasma spraying gun, the precursor solution is subjected to evaporation, decomposition, nucleation, heating and acceleration and collided by molten particles, and accordingly the semiconductor gas-sensitive coating is prepared over the interdigitated electrode.The defects in the prior art are overcome.The method can be used for preparing a nano porous structure semiconductor gas-sensitive coating, the coating is ultra-thin, oxygen deficiency concentration in the coating is adjustable, a material band gap is reduced, sensitivity is high, response speed is high, no external heating source is needed, the structure is simple, and reliability is high.

The invention especially relates to a radioactive C-MET-targeted affinity micromolecular compound and application thereof, belonging to the field of medical diagnosis and treatment. According to the invention, in-vivo tracking and imaging of diseases like tumors is realized through radiolabeling of a C-MET receptor antagonist. The radioactive C-MET-targeted affinity micromolecular compound can be used for monitoring the characteristics of biochemical changes of a hepatocyte growth factor receptor, visually displays the distribution and quantity of C-MET and is applicable to specific detection of a plurality of cancers including glioma, lung cancer, prostatic cancer, breast cancer, esophagus cancer, stomach cancer, liver cancer, pancreas cancer, ovarian cancer, rectal cancer and cervical cancer. The radioactive C-MET-targeted affinity micromolecular compound also has certain anticancer activity and has wide clinical application prospect.

The invention belongs to the field of medical embolization devices, relates to a sodium alginate microsphere targeted vascular embolization agent containing an antineoplastic drug and a preparation method thereof. Alginic acid is taken as a pharmaceutical carrier, the antineoplastic drug etoposide is a pharmaceutical active ingredient, divalent metal cation or calcium ion solution is taken as a solidifying agent, and the sodium alginate encapsulates the etoposide to prepare ideal particle size-controllable sodium alginate microspheres comprising the etoposide, thus avoiding toxic side effect of traditional etoposide administration such as anaphylaxis and inconvenience. The vascular embolization agent changes the dosage form and route of administration way of the antineoplastic drug etoposide, has high efficacy and low toxicity, and is safely and effectively applied to clinical application. The vascular embolization agent has the advantages of mild preparation condition and simple and convenient operation, and is fit for large-scale production. The vascular embolization agent can be used for vascular embolization, local targeted tumor treatment, and treating small-cell carcinoma of the lung, oophoroma, carcinoma of testis, gastric cancer and liver cancer by administering the vascular embolization agent during operations.

The invention relates to a triple compound microsphere vascular targeted embolization sustained-release preparation containing an antituberculous drug as well as a preparation method and application of the preparation. The sustained-release agent comprises a carrier and drugs, wherein the drugs are coated with the carrier; the carrier is sodium alginate or chitosan, and the drugs are triple antituberculous compound drugs including rifampicin, isoniazid and pyrazinamide or moxifloxacin. The three antituberculous drugs are matrix drug solutions, the sodium alginate or chitosan is a carrier solution, the matrix drug solutions and the carrier solutiona are mixed to prepare a solution, the polymer solution containing drugs is dispersed into fogdrops with a certain diameter by adopting a high-voltage electrostatic droplet mode, and the fogdrops are sprayed into a solidifying liquid to prepare antituberculous drug microspheres under the action of calcium ions. The embolization sustained-release preparation can be used for treating tuberculosis, massive hemoptysis of pulmonary tuberculosis, tuberculosis cavity, renal tuberculosis, osteoarticular tuberculosis, genital tuberculosis, tuberculosis of thyroid gland, tuberculosis of cervical lymph nodes, tuberculosis of pericardium, tuberculosis of chest wall, pleural tuberculosis and other kinds of tuberculosis in a body.

The invention belongs to the field of diagnostic imaging and relates to a GRPR targeted molecular probe and a preparation method thereof. The general formula of the GRPR targeted molecular probe is M-X-JMV594, wherein M is a signal component, X is a connector, and JMV594 is the targeted affinity component of GRPR; the JMV594 is a polypeptide sequence D-Phe-Gln-Trp-Ala-Val-Gly-His-Sat-Leu-NH2, and the signal component M is the combination of radioactive isotope with one or more of metal chelating agent, fluorescent dye, quantum dots, paramagnetic materials, super-paramagnetic materials, magnetic nano particles, ultrasonic microbubbles and photo-acoustic nano particles. The GRPR targeted molecular probe can be used as an image developing agent or radiotherapy medicine, has a good pharmacokinetics feature and a good biology distribution feature, and is accurate in detection result and promising in clinical application prospect.

The invention discloses a compound herbicide for preventing and removing ligularia virgaurea as well as a preparation method and an application method thereof. The compound herbicide is composed of the following raw materials in percentage by weight: 2%-40% of tribenuron-methyl, 5%-40% of clopyralid, 40%-90% of bentazone and the balance being auxiliary agents. The preparation method of the compound herbicide comprises the following steps: adding the tribenuron-methyl, the bentazone and the clopyralid, which are weighed according to the weight ratio, into an agitator; adding 5L-20L of tap water and agitating uniformly at a low speed; then adding sodium dodecyl benzene sulfonate, alkylphenol polyoxyethylene and polytrisiloxane according to the weight ratio; sufficiently agitating and uniformly mixing; and filling bottles and sealing. The application method of the compound herbicide comprises the step of spraying the compound herbicide on stems and leaves of ligularia virgaurea at a flowering period, wherein the herbicide spraying amount is 750-3000 g/hectare. The compound herbicide has high selectivity, special target and obvious prevention and removing effects on the specific plant, ligularia virgaurea, has a good ecological effect and can protect the biological diversity of grass lands very well.

The invention provides a multivalent aptamer DNA nano ladder and a preparation method and application thereof. Natural DNA molecules are used as raw materials, on the basis of the DNA origami theory,the DNA nano ladder is constructed by utilizing the special property of a rolling circle amplification product, a large number of aptamers are introduced, a drug delivery system which is simple in design and high in drug loading capacity and has target specificity and biocompatibility is constructed, and through aptamer or drug replacement, the carrier can also be applied to various types of target cells.

The invention relates to a vascular targeting embolism sustained release agent of a triple compound microsphere for an antituberculosis drug, a preparation method and applications thereof. The sustained release agent comprises a carrier and a drug, wherein the drug is encapsulated by the carrier, the carrier is selected from sodium alginate or chitosan, and the drug is a triple compound antituberculosis drug which comprises rifampin, isoniazide and pyrazinamide or moxifloxacin. Three antituberculosis drugs are employed as matrixes of a drug solution, sodium alginate or chitosan is used as a carrier solution, and a prepared solution is obtained by mixing the drug solution and the carrier solution. A polymer solution having the drug is enabled to be dispersed into droplets with certain particle sizes and to be sprayed into a curing liquid through a method of high voltage electrostatic droplets, and thus the microsphere for the antituberculosis drug are prepared in the presence of calcium ions. The embolism sustained release agent can be used in the drug for treating pulmonary tuberculosis, pulmonary tuberculosis massive hemoptysis, cavitary pulmonary tuberculosis, renal tuberculosis, osteoarticular tuberculosis, genital tubercolosis, thyroid tuberculosis, tuberculosis of cervical lymph nodes, pericardial tuberculosis, chest-wall tuberculosis and other in-vivo tuberculosises.

The invention provides a recombinant molecule of a human immunodeficiency virus film molecule gp120 functional domain and human TGF (Transforming Growth Factor)-beta1 and a preparation method and an application thereof, belonging to the technical field of biology. The molecule is formed by connecting a gp120 C2-C4 region with the human TGF-beta1 through a flexible linker. The C2-C4-linker-hTGD-beta can be used for activating and enhancing the function of a peripheral blood static CD4+CD25+regulatory T cell, can be selectively applied to a CD4+D25-initial T cell, contributes to transforming the CD4+D25-initial T cell into a CD4+D25-regulatory T cell, and is used for increasing CD4+D25-regulatory T cells in peripheral blood; and a new strategy is provided for clinical treatment of autoimmune diseases and transplanting-related diseases.

The invention provides a polyethylene glycol modified calcium-based nano-drug delivery particle, a preparation method thereof and an application. The particle size of the polyethylene glycol modified calcium-based nano-drug delivery particle is 20-200 nanometers, the polyethylene glycol modified calcium-based nano-drug delivery particle comprises a first target delivery material and a calcium-based particle wrapped with the first target delivery material, the surface of the calcium-based particle is modified with polyethylene glycol, the first target delivery material comprises a biological drug, a chemical drug or a second target delivery material entrapped with nucleic acid fragments, and the second target delivery material entrapped with the nucleic acid fragments is a cationic polymer, polypeptide, polyamino acid or transfection reagent wrapped, combined or blended with the nucleic acid fragments. The particle size of the nano-particle can be controlled in the preparation process of the polyethylene glycol modified calcium-based nano-drug delivery particle, the surface of the calcium-based particle is protected by a polyethylene glycol chain, so that in vivo circulation time is prolonged, and the particle is low in preparation cost, low in toxicity, safe and effective.

The present invention provides methods for production and purification of active chromoproteins produced by Actinomadura sp. 21G792. The chromoproteins are useful for developing pharmaceutical compositions and treating diseases such as cancer or bacterial infections.

The invention provides the application of a medicine or a product prepared by aptamer and used for treating multiple myeloma. The aptamer adopts TY04, and belongs to single strand DNA containing 83 basic groups. The action principle of the aptamer is that the aptamer can present cell specificity and sequence specificity and be stably combined with protide substances on the surface of multiple myeloma cells, operate the expression of related protein of cyclin B, CDK1, ERK1/2 and gamma-tubulin by lowering the cell cycle, and retard the process of multiple myeloma cell cycle to G2/M phase, thereby restraining the multiplication of the multiple myeloma cells. Presently, the aptamer for treating multiple myeloma is not reported at home and abroad. The discovery and application of the aptamer can provide a novel strategy for treating multiple myeloma.

The invention discloses a genetic micro-chain carrier, which comprises a linear DNA sequence expression cassette and two symmetrically arranged Cap protection sequences; wherein the Cap protection sequences close both ends of the linear DNA sequence expression cassette and are modified forming different protection structures, based by the building of MEKK1 micro-chain carrier specifically expressing inside the tumour relative with EB virus. The invention simultaneously discloses a construction method of the genetic micro-chain carrier. The invention has the advantages of good versatility of loading foreign gene and convenient replacement, since the linear nucleic acid structure of the micro-chain carrier comprises a replaceable target gene expression cassette; the chance to be a popular carrier of gene therapy, providing a new thinking and direction for the carrier development of gene therapy.

The invention relates to a method for establishing a cavernous body fibrosis disease model. The method comprises the following steps: (1) separating endothelial cells of a cavernous body and carrying out XMU-MP-1 treatment on the endothelial cells of the cavernous body; (2) carrying out immunofluorescence staining on the cell slide; (3) carrying out in-vitro culture and XMU-MP-1 treatment on the cavernous body tissue; (4) performing Masson dyeing on the cavernous body tissue paraffin section; and (5) carrying out XMU-MP-1 treatment on the in-vivo cavernous body of the rat, so as to obtain the required endothelial-mesenchymal transition mediated cavernous body fibrosis rat model. According to the invention, the blank of lack of a cavernous body fibrosis model caused by endothelial-mesenchymal transition at present is filled, and the development of in-vivo and in-vitro experiments of the phenomenon is greatly facilitated. The XMU-MP-1 used in the invention is used for activating a Hippo pathway of cavernous body fibroblasts, has small influence on other biological processes causing cavernous body fibrosis, such as fibroblast-myofibroblast conversion, fibroblast proliferation and the like, and has target specificity. Therefore, aiming at the biological process of endothelial-mesenchymal transformation, the interference can be eliminated by using the method for modeling.